<DOC>
	<DOCNO>NCT02254018</DOCNO>
	<brief_summary>maximum tolerate dose ( MTD ) , safety , pharmacokinetics , efficacy bivatuzumab mertansine</brief_summary>
	<brief_title>Single Dose Escalation Study Bivatuzumab Mertansine Patients With Advanced Squamous Cell Carcinoma Head Neck</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Maytansine</mesh_term>
	<criteria>1. male female patient age 18 year old 2. patient histologically confirm squamous cell carcinoma head neck 3. patient local / regional recurrent disease distant metastases refractory amenable establish treatment 4. measurable tumour deposit one radiological technique ( MRI , CT ) 5. life expectancy least 6 month 6 . Eastern Cooperative Oncology Group ( ECOG ) performance score ≤ 2 7. patient must give write informed consent ( must consistent International Conference HarmonisationGood Clinical Practice ( ICHGCP ) local legislation ) 1. hypersensitivity humanise murine antibody , immunoconjugates excipients trial drug 2. know secondary malignancy require therapy 3. active infectious disease 4. brain metastasis 5. neuropathy grade 2 ( exclude preexist neuropathy cranial nerve due surgery , radiotherapy tumour growth ) 6. absolute neutrophil count less 1,500/mm3 7. platelet count less 100,000/mm3 8. bilirubin great 1.5 mg/dl ( &gt; 26 μmol/L , système internationale ( SI ) unit equivalent ) 9. aspartate amino transferase ( AST ) and/or alanine amino transferase ( ALT ) great 3 time upper limit normal 10. serum creatinine great 1.5 mg/dl ( &gt; 132 μmol/L , SI unit equivalent ) 11. concomitant nononcological disease consider relevant evaluation safety trial drug 12. chemo immunotherapy within past three week prior treatment trial drug trial 13. radiotherapy head neck region within past four week inclusion trial 14. men woman sexually active unwilling use medically acceptable method contraception 15. pregnancy lactation 16. treatment investigational drug participation another clinical trial within past three week start therapy concomitantly trial 17. patient unable comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>